Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom1
Richard G. Pebody
, Ross Harris, George Kafatos, Mary Chamberland, Colin Campbell, Jonathan S. Nguyen-Van-Tam, Estelle McLean, Nick Andrews, Peter J. White, Edward Wynne-Evans, Jon Green, Joanna Ellis, Tim Wreghitt, Sam Bracebridge, Chikwe Ihekweazu, Isabel Oliver, Gillian E. Smith, Colin Hawkins, Roland Salmon, Brian Smyth, Jim McMenamin, Maria Zambon, Nick F. Phin, and John M. Watson
Author affiliations: Author affiliations: Health Protection Agency, London, UK (R.G. Pebody, R. Harris, G. Kafatos, M. Chamberland, C. Campbell, J.S. Nguyen-Van-Tam, E. McLean, N. Andrews, P.J. White, E. Wynne-Evans, J. Green, J. Ellis, T. Wreghitt, S. Bracebridge, C. Ihekweazu, I. Oliver, G. Smith, C. Hawkins, M. Zambon, N. Phin, J.M. Watson); Imperial College, London (P.J. White); Public Health Wales, Cardiff, Wales, UK (R. Salmon); Public Health Agency Northern Ireland, Belfast, Northern Ireland (B. Smyth); Health Protection Scotland, Glasgow, Scotland (J. McMenamin)
Figure 2. Days from symptom onset date of household primary case-patient with pandemic (H1N1) 2009 virus infection until antiviral prophylaxis started, N = 352, United Kingdom, 2009.
Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.